FIRST MANHATTAN CO. LLC. - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 41 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
FIRST MANHATTAN CO. LLC. ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q2 2022$1,0000.0%5000.0%0.00%
Q1 2022$1,000
-50.0%
5000.0%0.00%
Q4 2021$2,000
+100.0%
5000.0%0.00%
Q3 2021$1,0000.0%5000.0%0.00%
Q2 2021$1,0000.0%5000.0%0.00%
Q1 2021$1,000
-50.0%
5000.0%0.00%
Q4 2020$2,000
-97.0%
500
-87.5%
0.00%
Q3 2020$67,000
+52.3%
4,0000.0%0.00%
Q2 2020$44,000
+144.4%
4,0000.0%0.00%
Q1 2020$18,000
+5.9%
4,0000.0%0.00%
Q4 2019$17,000
+13.3%
4,0000.0%0.00%
Q3 2019$15,000
+15.4%
4,000
+14.3%
0.00%
Q2 2019$13,000
-13.3%
3,5000.0%0.00%
Q1 2019$15,000
+25.0%
3,5000.0%0.00%
Q4 2018$12,000
-7.7%
3,5000.0%0.00%
Q3 2018$13,0000.0%3,5000.0%0.00%
Q2 2018$13,000
+18.2%
3,5000.0%0.00%
Q1 2018$11,000
-15.4%
3,5000.0%0.00%
Q4 2017$13,000
-7.1%
3,5000.0%0.00%
Q3 2017$14,0003,5000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q1 2022
NameSharesValueWeighting ↓
Ikarian Capital, LLC 189,935$311,4940.08%
ABNER HERRMAN & BROCK LLC 280,000$4590.07%
Weaver Consulting Group 65,947$108,1530.06%
S.C. Financial Services, Inc. 25,372$41,6100.03%
JMAC ENTERPRISES LLC 40,430$66,3050.02%
Weaver Consulting Group 53,500$10,0470.01%
IFP Advisors, Inc 26,650$1390.00%
Bangor Savings Bank 4,000$70.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$4,9200.00%
BOOTHBAY FUND MANAGEMENT, LLC 19,098$31,3210.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders